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Proof-of-concept for a successful adeno-associated virus 
serotype 5 (AAV5)-mediated gene therapy in X-linked 
juvenile retinoschisis (XLRS) has been demonstrated in 
an established mouse model for this condition. The initial 
studies concentrated on early time-points of treatment. 
In this study, we aimed to explore the consequences of 
single subretinal injections administered at various stages 
of more advanced disease. By electroretinogram (ERG), 
functional improvement in treated versus untreated eyes 
is found to be significant in retinoschisin-deficient mice 
injected at the time-points of 15 days (P15), 1 month 
(PM1), and 2 months (PM2) after birth. In mice treated 
at 7 months after birth (PM7), an age previously shown 
to exhibit advanced retinal disease, ERG responses 
reveal no beneficial effects of vector treatment. Gener-
ally, functional rescue is paralleled by sustained retinos-
chisin expression and significant photoreceptor survival 
relative to untreated eyes. Quantitative measures of 
photoreceptors and peanut agglutinin–labeled ribbon 
synapses demonstrate rescue effects even in mice 
injected as late as PM7. Taken together, AAV5-mediated 
gene replacement is beneficial in slowing disease pro-
gression in murine XLRS. In addition, we show the effec-
tiveness of rescue efforts even if treatment is delayed 
until advanced signs of disease have developed. Human 
XLRS patients might benefit from these findings, which 
suggest that the effectiveness of treatment appears not 
to be restricted to the early stages of the disease, and 
that treatment may prove to be valuable even when 
administered at more advanced stages.
Received 16 October 2007; accepted 27 February 2008; published online 
25 March 2008. doi:10.1038/mt.2008.57
INTRODUCTION
X-linked juvenile retinoschisis (XLRS) (OMIM #312700) was first 
described over 100 years ago1 and, since then, it is known to be 
one of the more frequent hereditary retinal disorders affecting 
macular function in individuals of the male gender.2 A hallmark 
of the disease is the localized splitting of the central retina. In 
most patients, visual acuity is reduced to 20/100 although this can 
vary greatly.3,4 Thus far, treatment of XLRS has been limited to the 
prescription of low-vision aids. Surgical interventions benefit the 
patient only in rare cases.
An important functional test for XLRS is the full-field electro-
retinogram (ERG). Typically, a bright flash of light elicits a so-called 
negative response from the diseased retina, in which the a-wave is 
relatively preserved while the b-wave is nearly absent as compared 
to findings in a normal eye. The origin of this abnormality resides in 
the ON- and OFF-pathways at the level of the bipolar cells,5 point-
ing to an important structural locus of disease pathology.
RS1 is the causative gene associated with XLRS and encodes 
a retina-specific 24 kd protein, named retinoschisin.6 It is secre-
ted mainly from photoreceptors as a disulfide-linked homo-
oligomeric complex that is primarily localized to the outer surface 
of the inner segments of cones and rods but is also seen in the 
outer nuclear layer (ONL) and outer plexiform layer and in the 
bipolar cells of the inner nuclear layer (INL).7–11 The mature pro-
tein consists almost exclusively of a discoidin domain,12 a highly 
conserved module that likely mediates cell–cell interaction.13,14
The spectrum of RS1 mutations comprises mostly missense 
mutations, followed by frame shift and nonsense mutations, as 
well as those probably resulting in a deficiency of functional pro-
tein. Disease-linked missense mutations have been shown to lead 
to misfolded, aggregated proteins that are mostly retained in the 
endoplasmic reticulum.9,15 Together, these findings suggest that lack 
of functional retinoschisin underlies disease pathology. This raises 
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the possibility that replacement of the missing protein may be ben-
eficial to patients regardless of the specific type of RS1 mutation.
We16 as well as others17 have provided proof-of-concept for 
gene replacement in XLRS by demonstrating that intraocular 
adeno-associated virus (AAV) delivery of retinoschisin results in 
a significant recovery of retinal structure and function.17,18 In our 
study, a subretinal injection of an AAV serotype 5 vector contain-
ing the human RS1 gene under the control of the mouse opsin 
promoter (AAV5-mOPs-RS1) was administered at postnatal day 
15 (ref. 16). This has led to a significant functional recovery and 
improved structural organization of the retina coinciding with 
the presence and distribution of retinoschisin in the treated eyes. 
Most notably, and in contrast to the untreated eye, the treated ret-
ina revealed an almost normal organization of the INL and ONL 
and an absence of gaps between bipolar cells.16,18 There was also 
increased thickness of the ONL as a consequence of enhanced 
photoreceptor survival and a remarkable improvement in the 
structural integrity of the outer plexiform layer and INLs. A simi-
lar functional and structural rescue was found by Zeng et al.,17 and 
in a recent follow-up by Kjellstrom et al.,19 who evaluated AAV2-
CMV-Rs1h treatment efficacy at 14 months after a single vector 
injection of the murine Rs1h gene at P14. This study also provided 
evidence for long-term rescue of rod outer and inner segments, 
reduced photoreceptor cell death, and relative preservation of 
ERG responses.
In this study, we aimed to systematically explore the effects 
of a single subretinal AAV5-mOPs-RS1 injection into the reti-
noschisin-deficient (Rs1h−/−) mouse retina at various stages of 
disease progression. In the context of a potential AAV-mediated 
gene replacement therapy option for humans with the disease, 
this issue assumes immediate importance, because the majority of 
patients may already have various degrees of disease pathology at 
the time they first present for treatment.
RESULTS
Time course of RS1 protein expression after 
subretinal injection of AAV5-mOP-RS1
As shown earlier, delivery of AAV5-mOP-RS1 to the subreti-
nal space in Rs1h-deficient mice resulted in a time lag before an 
improvement in the ERG b-wave amplitude was found.16 The ERG 
showed no improvement in the b-wave amplitude 1 month after 
the injection, while a modest increase in the b-wave amplitude 
was observed at PM2. Three months after the injection, a signifi-
cant increase in b-wave and a small but significant increase in the 
a-wave were observed. In order to determine whether retinoschi-
sin expression and localization correlate with this delay in func-
tional recovery, we examined retinal cryosections for retinoschisin 
at various time-points from 1 week to 12 weeks after subretinal 
injection of vector into 15-day-old retinoschisin-deficient mice. 
The typical pattern of protein expression is shown in Figure 1. No 
RS1 expression was observed 1 week after injection and only a few 
sporadically distributed photoreceptors were positive for retinos-
chisin at 2 weeks after injection. The number of labeled photore-
ceptors increased between the time-points of 3 weeks and 8 weeks 
after injection, and by 12 weeks almost all the photoreceptors 
across the retina were intensely labeled. Labeling of retinoschisin 
also increased along the longitudinal axis of the retina (Figure 1). 
At 2 weeks after injection, RS1 labeling was restricted to the inner 
segments of the photoreceptors. At 3 and 4 weeks after injection, 
RS1 labeling had spread to the ONL, with weak labeling observed 
in the outer plexiform layer. At 8 and 12 weeks after injection, 
more intense labeling was observed in the outer plexiform layer, 
with labeling observed to extend into the INL. This pattern of 
labeling is consistent with the expression and secretion of RS1 
originating from the inner segments of photoreceptor cells and 
spreading to the other retinal layers. As the external surface of the 
inner segment becomes saturated with retinoschisin, the external 
surfaces of the photoreceptors’ ONLs and outer plexiform layers 
become labeled. In this manner, over time, retinoschisin makes 
its way into the inner retina where it binds to the surface of the 
retinal bipolar cells, as observed earlier in the retinas of wild-type 
mice.8,16 Recent studies indicate that RS1 binding to the surface of 
photoreceptor and bipolar cells is mediated through its interac-
tion with Na/K ATPase.20
The finding that retinoschisin labeling is present in the outer 
plexiform layer at 8 and 12 weeks after injection is consistent with 
the improvement in ERG b-wave amplitudes observed at these 
time-points.
Time course of photoreceptor degeneration in the 
retinoschisin-deficient mouse
We have shown earlier that photoreceptor cell death in the Rs1h-
deficient mouse is triggered by apoptotic events initiating at 
around P14 (refs. 21, 22). Histologically, this becomes evident in a 
progressive reduction in ONL thickness over time.18,19 In order to 
further refine the time course and quantify the loss of photorecep-
tor cells in the Rs1h-deficient retina, we determined the number 
of cones and layers of the photoreceptor nuclei in the ONL over a 
10-month period of disease progression (Figure 2). These values 
were compared to age-matched wild-type mice at three time-
points from 15 days after birth to 13 months of age. Retinoschisin- 
deficient mice were analyzed at PM0.5, PM1, PM4, PM5, PM6, 
and PM10. At PM0.5 (15 days after birth), shortly before the 
major burst of apoptotic photoreceptor cell death occurs around 
P18 (18 days after birth) (refs. 21, 22), the photoreceptor nuclei 
count in Rs1h-deficient mice is almost identical to that in wild-
type animals (94.1 ± 8.3; P = 0.08). In addition, as in age-matched 
wild-type controls, the knockout animals reveal ~500 cones per 
retinal section (Figure 2 and data not shown). The further course 
of cell loss in the diseased retina follows a two-phase pattern, with 
an initially dramatic decrease of photoreceptors (>40%) within 
the first month of age. Thereafter, photoreceptor cell loss appears 
to slow and adopts a linear progression, with an average rate of cell 
death of 9.3 ± 2.0% (P < 0.001) per month. At 10 months of age, 
~84% of the photoreceptors are lost in the diseased retina.
Subretinal AAV5-mOPs-RS1 injections at various 
stages of disease progression
ERG responses. As shown earlier, ERG b-wave amplitudes are 
well suited for assessing the beneficial effects of AAV-mediated 
gene replacement therapy in retinoschisin-deficient mice.16,19 
Four groups of mice, given a single unilateral subretinal injection 
at PM0.5 (three males and two females), PM1 (two males and five 
females), PM2 (five females), and PM7 (four males), respectively, 
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were included in the ERG analysis (Supplementary Table S1). 
The time period between treatment and the recording of ERGs was 
maintained at 4 months. That is, ERGs were recorded at PM4.5 
(group 1), PM5 (group 2), PM6 (group 3), and PM11 (group 4). 
A prominent increase in b-wave amplitude was observed in the 
treated eye relative to the untreated eye in mice that had been 
treated at 15 days after birth (Figure 3a). This is in full agreement 
with our earlier data.16 An injection at PM1 still had a substantial 
positive effect 4 months later (Figure 3b), and a minor improve-
ment was recordable in the group treated at PM2 (Figure 3c). 
Treatment at 7 months of age resulted in poor responses in retinal 
function when analyzed at 11 months after birth, with results sim-
ilar to those in the untreated control eyes (Figure 3d). In order 
to assess potential differences between rod- and cone-system 
 responses, we additionally recorded ERGs under photopic condi-
tions. The positive effect on the cone system was approximately 
proportional to that on the rod system (lower pair of curves in 
Figure 3a–d). Statistical evaluation of the data reveals significant 
results for both scotopic and photopic recordings at PM0.5, PM1, 
and PM2 (Figure 3e and f). This suggests either a direct benefit 
of the treatment on cone survival and functionality or, alterna-
tively, an indirect effect mediated through rod persistence, given 
that cone survival depends on rod integrity. The morphological 
status of rod and cone cells was then studied histologically for 
each treatment group.
Histology and immunohistochemistry. Animals included in the 
ERG study were killed at PM4.5 (group 1), PM9 (group 2), PM10 
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Figure 1 Immunofluorescence labeling of RS1 in retinal sections of Rs1h-deficient mice at various times after AAV5-mOP-RS1 treatment. 
Subretinal injections were carried out on 15-day-old retinoschisin-deficient mice. Retinal cryosections at the indicated postinjection time-points 
were labeled with an anti-RS1 antibody and goat anti-rabbit immunoglobulin-tagged with Cy3 (green) and counterstained with 4ʹ,6-diamidino-2- 
phenylindol nuclear (blue) dye to define the nuclear layers. Left: low-magnification image of the retina showing lateral distribution of label as a func-
tion of postinjection time-points; right: higher-magnification image of more densely stained regions of the retina showing longitudinal distribution of 
RS1 staining in the retinal layers. INL, inner nuclear layer; IS, inner segment; ONL, outer nuclear layer; OPL, outer plexiform layer.
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(group 3), and PM15 (group 4), and assessed for RS1 expression 
and tissue distribution by labeling retinal cryosections with poly-
clonal antibody RS1-3R10 (Figure 4a–d). As expected, untreated 
eyes remained unstained, demonstrating that RS1 protein is ab-
sent throughout the retina; the untreated eyes served as internal 
controls for natural disease progression. In contrast, RS1-specific 
labeling was present in AAV5-mOP-RS1-treated retinas from all 
four groups of mice. Eyes injected at PM0.5 (group 1) showed 
strong expression and a pattern of protein distribution nearly 
identical to that found in wild-type mice (Figure 4a). The eyes 
from the vector-treated as well as the age-matched wild-type mice 
revealed intense RS1 staining of photoreceptor inner segments 
and weaker labeling of the ONL and outer plexiform layer. There 
was also distinct immunostaining of the outer membranes of the 
retinal bipolar cells and labeling of the inner plexiform layer. 
These findings are fully consistent with the data from our earlier 
study.16 Eyes injected at PM1 (Figure 4b), PM2 (Figure 4c), and 
PM7 (Figure 4d) still showed strong RS1 labeling at the level of 
the photoreceptor inner segments, but exhibited attenuated ONL 
thickness and disturbances in retinal structure well correlated 
with the stage of disease progression at the time of treatment. RS1 
labeling of retinal bipolar cells and the inner plexiform layer after 
treatment at PM1 and PM2 is similar to that in the retinas of wild-
type animals but decreases markedly in retinas treated at PM7.
Photoreceptor survival in AAV5-mOPs-RS1-treated versus 
untreated eyes was quantified by two measures. First, by fluores-
cence-conjugated peanut agglutinin which specifically labels cone 
photoreceptors and photoreceptor-bipolar synaptic regions; and 
second, by 4ʹ,6-diamidino-2-phenylindol nuclear dye staining 
which identifies both cone and rod photoreceptor nuclei in the 
ONL (Figure 4a–d). In untreated eyes, the number of cones as 
well as the number of layers of photoreceptor nuclei follow a lin-
ear decrease with an average of 131.6 ± 40.3 cones/section (6.0 ± 
0.5 rows of nuclei/section) for group 1 animals (27 retinal sec-
tions analyzed) and 34.8 ± 23.2 cones/section (2.5 ± 0.6 rows of 
nuclei/section) for group 4 mice (21 retinal sections analyzed) 
(Figure 5a and b, Table 1). This leads to a calculated rate of loss 
of photoreceptor cells of ~10.2% per month, in good agreement 
with the rates established for the general course of disease pro-
gression (Figure 2). For vector-treated eyes, both the loss of cones 
(P ≤ 2.3 × 10−8) as well as the overall loss of rows of photorecep-
tor nuclei (P ≤ 8.5 × 10−4) were significantly less pronounced as 
in partner untreated eyes in each of the four groups analyzed 
(Figure 5a and b). On average, there was a (2.7 ± 0.5)-fold higher 
cone count and a (1.9 ± 0.4)-fold increase in the rows of photore-
ceptor nuclei in treated versus untreated eyes following each time-
point of injection.
Taken together, morphological changes in untreated eyes 
closely followed the known course of retinal degeneration in 
retinoschisin-deficient mice, as described earlier.18,19 Most nota-
bly, all the age groups that were studied showed a significant loss 
of photoreceptor cells, in particular cones, closely accompanied 
by an almost complete loss of peanut agglutinin–labeling of rib-
bon synapsis (Figure 4a–d). Retinas treated at progressively later 
time-points of disease progression showed progressively less pres-
ervation. However, whatever the time-point at which the treat-
ment was given, the rate and extent of degeneration in the treated 
eye were significantly less pronounced at the time of evaluation 
than in the untreated control eye of the same animal (Figures 4 
and 5). At PM1 and PM2, and even in the most advanced age 
group (PM7), AAV5-mOPs-RS1-injected eyes still retained a 
retinal architecture that represented a marked improvement over 
the control eyes, as determined on the basis of (i) preservation of 
photoreceptor cells, including cones; (ii) the presence of photore-
ceptor-bipolar synaptic ribbons; (iii) thinned but preserved ONL 
and INL; and (iv) histologically distinct inner and outer plexiform 
layers (Figure 4a–d).
DISCUSSION
In this study, we explored the efficacy of AAV-mediated gene 
replacement in a well-established mouse model of XLRS as a func-
tion of the stage of the disease. We show that a significant func-
tional benefit of therapy (in terms of ERG responses) is detectable 
even in mice that received treatment only as late as 2 months 
after birth. This functional recovery is reflected in the preserva-
tion of retinal architecture in the treated eyes as compared to the 
untreated ones, and by the presence of a retinal distribution of 
expressed retinoschisin that is remarkably similar to that seen 
in retinas of wild-type mice. Most notably, photoreceptor cell 
preservation is 2.3-fold higher in treated eyes in comparison 
with untreated eyes, independent of the time-point (after birth) 
at which vector treatment was administered. This is consistent 
with findings in an independent study, where retinoschisin- 
deficient mice were treated with AAV 2-CMV-Rs1h as late as 
PM3.17 Although retinoschisin replacement at this late time-point 
of initiation of treatment did not result in repair of the retinal 
structure, it was nevertheless successful in reversing the functional 
abnormality of the b-wave. Together, these findings bode well for 
future gene therapy trials in humans, as they suggest that AAV-
mediated delivery of retinoschisin into the diseased retina might 
be beneficial to patients even when treatment is administered at a 
relatively advanced disease stage.
An analysis of the documented time course of RS1 expression 
after subretinal injection of AAV5-mOP-RS1 in retinoschisin- 
deficient mice demonstrated that there is a delay of as much as 
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Figure 2 Evaluation of the extent of photoreceptor degeneration in 
retinal sections of Rs1h-deficient mice at various times after birth. 
Retinal cryosections of retinoschisin-deficient and wild-type (WT) mice 
were analyzed at the postnatal time-points indicated for the presence 
of cones (labeling with Alexa488 green-conjugated peanut agglutinin) 
(left y-axis) and photoreceptor nuclei (labeling with 4ʹ,6-diamidino-
2-phenylindol nuclear blue dye) (right y-axis). For each age group 
of animals, at least four eyes and three sections from each eye were 
included in the analysis. Bars represent mean number of cones (circles) 
and layers of photoreceptor nuclei (squares) ± SEM.
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2 months after the injection before protein distribution within the 
retina mimics the wild-type pattern. That is, the full rescue effect 
of vector treatment is realized only after functional retinoschisin 
is available at all retinal structures in which it is normally found. 
Given that RS1 expression takes place primarily in photoreceptors 
and then must be secreted and localized to its correct positions 
throughout the retina, it may not be surprising that protein distribu-
tion is delayed quite significantly relative to its simple expression in 
the photoreceptors. Considering that almost 40% of retinoschisin-
deficient photoreceptor cells die within the first month of birth, 
followed by a further loss of cones and rods at a rate of ~10% per 
month, we conclude that even early treatment (at postnatal day 15 
or PM1) may have to face the challenge of a retinal environment 
already suffering substantial (perhaps 50%) loss of photoreceptors. 
In this context, it is extraordinary that the rescue seen at the first 
two time-points of injection is so robust (ref. 16 and this study), 
and suggests that photoreceptors display tremendous plasticity in 
response to retinoschisin treatment. Even more surprising is the 
400a b
c d
e f
b-
wa
ve
 a
m
pl
itu
de
 (µ
v)
b-
wa
ve
 a
m
pl
itu
de
 (µ
v)
b-
wa
ve
 a
m
pl
itu
de
 (µ
v)
ER
G
 a
m
pl
itu
de
 s
id
e 
di
ffe
re
nc
e 
(µV
)
ER
G
 a
m
pl
itu
de
 s
id
e 
di
ffe
re
nc
e 
(µV
)
b-
wa
ve
 a
m
pl
itu
de
 (µ
v)
PM0.5
PM2 PM7
PM1
AAV-mOP-RS1
Scotopic
Uninjected
Photopic
350
300
250
200
150
100
50
0
−4 −3 −2
Stimulus intensity [log (cd·s/m2)] Stimulus intensity [log (cd·s/m2)]
Stimulus intensity [log (cd·s/m2)] Stimulus intensity [log (cd·s/m2)]
Age at time of injection (months) Age at time of injection (months)
−1 0 1 −4 −3 −2 −1 0 1
−4 −3 −2 −1 0 1 −4 −3 −2 −1 0 1
400
350
300
250
200
150
100
50
0
400
350
300
250
200
150
150
100
Scotopic ERG Photopic ERG
**
**
**
**
**
*
50
0
0 1 2 3 4 5 6 7 0 1 2 3 4 5 6 7
60
40
20
0
100
50
0
400
350
300
250
200
150
100
50
0
Figure 3 Electroretinogram (ERG) evaluation of AAV5-mOP-RS1 injections as a function of age at the time of treatment. (a–d) Electrophysiological 
evaluation of AAV-mOPs-RS1-treated and untreated control eyes from retinoschisin-deficient mice injected at (a) PM0.5, (b) PM1, (c) PM2, and 
(d) PM7, each analyzed 4 months after treatment. For each time-point of injection, dark-adapted (scotopic) and light-adapted (photopic) single-flash 
ERG b-wave amplitudes were recorded from treated eyes (red)  and untreated eyes (black) of the same mouse as a function of the logarithm of the 
flash intensity. Boxes indicate the 25–75% quantile range, whiskers indicate the 5 and 95% quantiles, and the asterisks indicate the median of the 
data. The green shading between treated eye and untreated eye medians indicates the functional benefit of treated eye over untreated eye in terms 
of ERG b-wave amplitude gain. (e and f) Statistical evaluation of (e) scotopic and (f) photopic ERG b-wave amplitude side differences for the time-
points shown in a–d. Each open triangle represents data from an individual mouse (see Materials and Methods for details), dots indicate the mean 
values across mice, and the line is a hyperbolic fit. Asterisks show the level of significance of the differences; *P < 0.05, **P < 0.01.
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vector-mediated retinal rescue seen after treatment at PM2, even 
though there would have been substantial photoreceptor loss, inner 
segment shortening of the remaining photoreceptors, and retinal 
disorganization at this time-point. This suggests that retinoschisin 
protein may be capable of rescuing diseased photoreceptors from 
apoptotic cell death, although retinoschisin alone does not appear 
capable of effecting a complete repair of all morphological retinal 
cell damage that predated the treatment.
ERG responses and the level of rescue of the retinal structure 
appear discordant at some time-points, with the beneficial effects 
of treatment on retinal structure being more evident than those 
on function at time-point PM2 and, to some extent, even at PM7. 
This may be because of progressive deterioration of functionally 
essential structures such as synapses, gap junctions, and cone ped-
icles, which may not be reversible by later treatment. Impairment 
of substructural elements may lead to “retired” cells that are mor-
phologically still present but do not contribute further to function. 
Alternatively, Ganzfeld ERG responses for treatment at advanced 
disease stages could fall below a recordable threshold although 
areas of functionality may still exist. In order to address this pos-
sibility, an improved resolution of multifocal ERG recordings 
may be required. Importantly, our findings emphasize the need 
for both functional and morphological follow-up approaches in 
therapy assessment studies.
In summary, this study builds on previous demonstrations of 
proof-of-concept of gene therapy in independent mouse models 
for XLRS. It delineates the window of rescue, in terms of disease 
duration at the time of vector injection. Accordingly, gene replace-
ment therapy at an early stage of the disease can effectively restore 
visual function, and there is a gradual decline in the rescue effect 
when treatment is administered at more advanced stages of the 
disease. This study demonstrates that, even when treatment is ini-
tiated only at an advanced stage of the disease, RS1 gene replace-
ment therapy may be successful in slowing disease progression 
and averting further photoreceptor cell death.
MATERIALS AND METHODS
Mice. The method of generation and the phenotypic characterization 
of the Rs1h-knockout mouse line used in this study have been reported 
 earlier.18 The line has been backcrossed for more than 10 generations 
onto a pure C57BL/6 background. A total of 33 Rs1h-deficient mice were 
injected with AAV5-mOP500-hRS1 at various time-points after birth: nine 
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Figure 5 Evaluation of photoreceptor cell rescue in AAV5-mOP-RS1-
treated versus untreated retinas of retinoschisin-deficient mice, in 
relation to the time-points at which treatment was administered. 
(a) The total number of cones per retinal section was counted after stain-
ing with Alexa488 (green)-conjugated peanut agglutinin. (b) Likewise, 
the number of rows of photoreceptor nuclei was determined per retinal 
section after 4ʹ,6-diamidino-2-phenylindol nuclear dye (blue) staining. 
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and untreated eyes were calculated using the paired Student’s t-test 
(*P ≤ 8.5 × 10−4; **P ≤ 2.3 × 10−8).
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type, treated, and untreated eyes of Rs1h-deficient mice at various 
time-points after AAV-mOP-RS1 injections. Subretinal injections were 
administered in retinoschisin-deficient mice at (a) PM0.5, (b) PM1, 
(c) PM2, and (d) PM7, while retinal cryosections were analyzed at the 
ages of (a) 4 months and (b–d) 8 months after injection. Labeling 
was done using Alexa488 (green)-conjugated PNA so as to specifically 
stain cone inner segments and photoreceptor-bipolar synaptic regions. 
For labeling of photoreceptor inner segments, RS1-3R10 (RS1) anti-
body and anti-rabbit immunoglobulin-tagged with Alexa488 (green) 
were used. Retinal sections were counterstained with 4ʹ,6-diamidino-2- 
phenylindol nuclear dye (blue) to define the nuclear layers. Data relating 
to untreated eye (left column) and treated eye (middle column) refer 
to the same individual mouse in each case. Data from age-matched 
control mice are shown for comparison on the right. GCL, ganglion cell 
layer; INL, inner nuclear layer; IS, inner segment; ONL, outer nuclear 
layer; OPL, outer plexiform layer; RPE, retinal pigment epithelium.
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 animals (four males and five females) at day 15 (PM0.5), ten (three males 
and seven females) at 1 month (PM1), seven (one male and six females) at 
2 months (PM2), and seven (six males and one female) at 7 months (PM7). 
The animals were reared under standard laboratory conditions (22 ± 2 °C, 
60 ± 10% relative humidity, and a 12-hour light–dark cycle) and had free 
access to food and water throughout the experiment. The conditions of 
housing and experiments were in accordance with the Association for 
Research in Vision and Ophthalmology Statement for the Use of Animals 
in Ophthalmic and Vision Research, and with the protocols approved by 
the University of Florida Institutional Animal Care and Use Committee and 
the Animal Care and Use Committee of the University of Regensburg.
Time course of AAV5-mOP500-hRS1 expression. The right eye of each of 
35 Rs1h-deficient mice was injected with AAV5-mOP500-hRS1 at post-
natal day 15. Seven mice were killed at 1 week, nine at 2 weeks, seven at 
3 weeks, five at 4 weeks, three at 8 weeks, and four at 12 weeks after the 
injection. The eyes were enucleated and fixed with 4% paraformaldehyde 
in 0.1 mol/l phosphate buffer (PB) (pH 7.4) containing 5% sucrose for 
1.5 hours and rinsed in PB containing 5% sucrose. The eyes were cryo-
protected with 8, 12, 16, and 20% sucrose, in PB before being frozen in 
OCT. Cryosections were blocked and permeabilized in 10% normal goat 
serum and 0.2% Triton X-100 in PB for 30 minutes and subsequently 
labeled overnight with anti-RS1 polyclonal antibody diluted 1:3,000 in PB 
containing 2.5% normal goat serum and 0.1% Triton X-100. Sections were 
rinsed in PB and labeled for 1 hour with goat anti-rabbit immunoglobulin 
conjugated with Cy3 (Cedar Lane, Burlington, Canada). Labeled retinal 
sections were examined under a Zeiss Axioplan2 fluorescence microscope 
equipped with an Eclipse digital analyzer.
In order to study the course of photoreceptor degeneration after 
vector injection at defined time-points postnatally, nine hemizygous 
male knockout mice were killed at PM0.5, PM1.5, PM4.5, PM6, and 
PM10. Eleven C57BL/6 wild-type animals, purchased from Charles River 
(Sulzfeld, Germany), served as age-matched controls.
AAV5-mOP500-hRS1 construct and delivery. Generation and delivery of 
the AAV5 vector containing the human RS1 cDNA under the control of the 
mouse opsin promoter (AAV5-mOPs-hRS1) has been described earlier.16 
Briefly, the full-length human RS1 was cloned into the pTR-AAV plasmid 
containing AAV-inverted terminal repeats and a proximal mouse opsin 
promoter (mOP-500) which restricts expression to photoreceptors. This 
serotype 2 vector DNA then packaged into serotype 5 capsids resulting in a 
pseudotyped vector, sometimes referred to as AAV2/5, but referred to here 
simply as AAV5. The titers of the vectors were adjusted to 4 × 1013 vector 
genomes/ml. Before the injection, the animals were anesthetized with IP 
ketamine (66.7 mg/kg) and xylazine (11.7 mg/kg), and the right eye of each 
mouse was dilated with 1% atropine sulfate and 2.5% phenylephrine hydro-
chloride. After the application of 2.5% hydroxypropyl methylcellulose (Eye 
Supply USA, Tampa, FL), the cornea was punctured carefully with a 30G1/2 
gauge needle guided by an operating microscope so as to avoid lens damage. 
A blunt 33-gauge needle (Hamilton, Reno, NV) was then inserted through 
the corneal hole, maneuvered around the lens, displacing it medially, and 
was directed toward the subretinal space of the inferior hemisphere. A total 
of 1 µl volume of vector with fluorescein tracer (0.1 mg/ml) was used for 
each injection. An antibiotic (Vetropolycin, Pharmaderm, NY) was applied 
daily to the cornea for 3 days following the procedure. The other (left) eye of 
each treated animal was left untouched and served as internal control.
Electroretinography. ERGs were performed according to proce-
dures described earlier.23 The ERG equipment consisted of a Ganzfeld 
bowl, a direct-current amplifier, and a personal computer–based control 
and recording unit (Multiliner Vision; Viasys Healthcare, Hoechberg, 
Germany). The mice were dark-adapted overnight and anesthetized using 
ketamine (66.7 mg/kg) and xylazine (11.7 mg/kg). The pupils were dilated, 
and single-flash ERG recordings were obtained under dark-adapted 
(scotopic) and light-adapted (photopic) conditions. Light adaptation 
was accomplished with a background illumination of 30 cd/m2 starting 
10 minutes before recording. Single white-flash stimulation ranged 
from 10−4 to 25 cd·s/m2, divided into 10 steps of 0.5 and 1 log cd·s/m2. 
Ten responses were averaged with an interstimulus interval of either 
5 seconds or 17 seconds (for 1, 3, 10, and 25 cd·s/m2). A statistical evalua-
tion of the ERG data was performed. First, b-wave amplitude differences 
between the treated and the untreated eyes were obtained for each animal 
at each intensity value of the stimulus supplied. For scotopic recordings, 
the median of these data across intensities from 10−2 to 25 cd·s/m² was 
determined for each mouse. For photopic recordings, only the difference 
at 25 cd·s/m² was used for each mouse. As saturation was not reached, this 
intensity yields the largest difference under the given conditions. These 
data are shown in Figure 3e and f as open triangles. A paired t-test was 
used for determining the level of significance of the differences between 
the treated and the untreated eyes across mice, separately for each time-
point of vector injection.
Histology and immunohistochemistry. The eye bulbs of treated and 
untreated eyes were removed and embedded in O.T.C. compound without 
fixation, with care being taken to hold the eyes in a standardized position 
(Tissue Tek; Sakura Finetek, Zoeterwoude, The Netherlands). In order to 
ensure that all retinal sections were derived from the same position of 
the central inner retina at the level of the anatomical midline of the eye, 
sections were cut sagittally on a cryostat (10 µm). The outline of the lens 
served as orientation. Mice injected at PM0.5 were analyzed 4 months 
after injection, while animals injected at PM1, PM2, and PM7 were killed 
for analysis 8 months after injection. Three retinal sections each from 
the injected right eye and the noninjected left eye of each animal were 
analyzed. For each retinal section, the total number of cones and layers 
of photoreceptor nuclei was counted along the longitudinal axis of the 
entire retina. The results were combined groupwise, and 27 (group 1), 
30 (group 2), 21 (group 3), and 21 (group 4) retinal sections were included 
in the statistical evaluation. The sections were postfixed in 4% parafor-
maldehyde at room temperature for 6 minutes and rinsed several times in 
phosphate buffered saline. The sections were then blocked (1% dry milk; 
0.1% Tween 20 in phosphate-buffered saline) for 30 min at room tem-
perature. Subsequently, the sections were stained with monoclonal anti-
body RS1-3R10 (1:250) specific to human retinoschisin,9 and with peanut 
agglutinin (1:800) specific to cone photoreceptor inner segments, in 2% 
Table 1 Quantitative measure of photoreceptor loss in AAV5-mOPs-RS1-treated and untreated retinae
Age at injection 
(month)
No. of mice 
analyzed
Untreated retinaa AAV5-mOPs-RS1-treated retinaa
No. of cones per 
section (±SD)
No. of rows of photoreceptor 
nuclei (±SD)
No. of cones per 
section (±SD)
No. of rows of 
photoreceptor nuclei (±SD)
0.5 9 131.6 ± 40.3 6.0 ± 0.5 407.0 ± 74.0 12.6 ± 1.7
1 10 111.5 ± 40.0 6.3 ± 1.2 300.9 ± 71.1 11.1 ± 1.4
2 7 95.1 ± 28.8 6.1 ± 0.8 184.7 ± 38.0 9.1 ± 1.3
7 7 34.8 ± 23.2 2.5 ± 0.6 102.8 ± 38.0 5.9 ± 0.7
aThree retinal sections per eye were analyzed, respectively.
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bovine serum albumin, 0.02% sodium azide, and 0.1% Triton X-100 in 
phosphate-buffered saline. Sections stained for RS1-3R10 were incubated 
with Alexa-conjugated secondary antibodies (1:1,000; Molecular Probes, 
Leiden, The Netherlands). The sections were counterstained with 4ʹ,6-
diamidino-2-phenylindol (Molecular Probes, Leiden, The Netherlands). 
The slides were mounted in Fluorescent Mounting Medium (Dako 
Cytomation, Glostrup, Denmark) and analyzed using an Axioskop 2 (Carl 
Zeiss, Oberkochen, Germany).
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